Jorge González-Bacerio

Dr. Jorge González-Bacerio

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
YCYosberto Cárdenas‐Moreno
Yosberto Cárdenas‐Moreno
JGJorge González-Bacerio
Jorge González-Bacerio
HAHumberto García Arellano
Humberto García Arellano
AMAlberto del Monte‐Martínez
Alberto del Monte‐Martínez

1 August 2010 in Biochimie
Verified
Journal Article
Closed access
LRLazara Romero
Lazara Romero
SMSilvana Marcussi
Silvana Marcussi
DMDaniela P. Marchi-Salvador
Daniela P. Marchi-Salvador
FSFloriano Silva-Jr
Floriano Silva-Jr
AFAndré L. Fuly
André L. Fuly
ASAndreimar Soares
Andreimar Soares

1 February 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YMYanira Méndez
Yanira Méndez
GAGerman De Armas
German De Armas
IPIdalia Pérez
Idalia Pérez
TRTamara Rojas
Tamara Rojas
MVMario S. Valdés-Tresanco
Mario S. Valdés-Tresanco
DRDaniel G. Rivera
Daniel G. Rivera

7 November 2014 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
JGJorge González-Bacerio
Jorge González-Bacerio
RFRafael Fando
Rafael Fando
AMAlberto Monte-Martinez
Alberto Monte-Martinez
JCJean-Louis Charli
Jean-Louis Charli
MCMaria de Los A. Chávez
Maria de Los A. Chávez
Malaria is a devastating human parasitic disease that receives enhanced attention due to the emergence of resistance to traditional drugs. Thus, the search for new molecular targets is a major goal. PfAM1 is an aminopeptidase from Plasmodium falciparum, William H. Welch 1897, belonging to the M1 family of metalloproteases, which is a promising target of inhibitors to block the intra-erythrocytic stages of the parasite. Since its identification in 1998, many efforts have been done to validate PfAM1 as an appropriate target of antimalarials. The present work is a critical review of the main structural, functional and kinetic characteristics of PfAM1, as well as a summary of the effects of key inhibitors at molecular and cellular levels. The systematization of experimental results should contribute to a better understanding of the properties of PfAM1 as a target of antimalarials and promote research projects focused on the development of PfAM1 inhibitors.

2 July 2014 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
YMYanira Méndez
Yanira Méndez
KPKarell Pérez‐Labrada
Karell Pérez‐Labrada
JGJorge González-Bacerio
Jorge González-Bacerio
GVGilberto Valdés
Gilberto Valdés
MCMaría Á. de Los Chávez
María Á. de Los Chávez
DRDaniel G. Rivera
Daniel G. Rivera

1 September 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JGJorge González-Bacerio
Jorge González-Bacerio
SMSarah El Chamy Maluf
Sarah El Chamy Maluf
YMYanira Méndez
Yanira Méndez
IPIsel Pascual
Isel Pascual
IFIsabelle Florent
Isabelle Florent
MGMarcos L. Gazarini
Marcos L. Gazarini